###### Strengths and limitations of this study

-   To the best of our knowledge, this will be the first systematic review and meta-analysis to summarise available data on venous thromboembolism (VTE) on the African continent.

-   A limited amount of data with predominance of hospital-based studies pose as a major restriction to this study, as the result may not reflect the true burden of VTE in the general African population.

-   Another possible limitation may be heterogeneity of studies done on the topic in Africa.

Introduction {#s1}
============

The recent increase in life expectancy has led to an epidemiological transition from communicable to non-communicable diseases worldwide.[@R1] As a result, Africa faces a growing epidemic of non-communicable diseases among which cardiovascular diseases (CVDs) remain the most frequent and a major cause of disease-associated mortality.[@R2] In 2012, the WHO estimated that CVDs were responsible for 17.5 million deaths globally, with over three quarters occurring in low and middle-income countries, such as those in Africa.[@R4] Although the increasing burden of CVDs in recent years has been attributed to an increase in the prevalence of atheromatous diseases, venous thromboembolic diseases (VTDs) still remain a major cause of CVD burden. VTDs englobe two main entities: deep vein thrombosis (DVT) and pulmonary embolism (PE); and is among the three major causes of CVDs worldwide after ischaemic heart disease and stroke.[@R6] VTD is a life-threatening condition associated with significant morbidity and mortality. Usually, DVT and PE occur as postoperative complications, affecting about 33% of patients undergoing an elective general surgical procedure.[@R7] Nevertheless, it complicates many medical conditions especially in patients admitted to the intensive care unit.[@R7] VTDs have various clinical presentations, and the disease severity depends on the size of the occluded vessel, the length, location and duration of obstruction. Among these locations, DVT of leg veins remains the most frequent, while PE and thrombosis of deep pelvic veins are considered the most common cause of death.[@R6] Some previous systematic reviews have evaluated the burden of venous thromboembolism (VTE) in various populations including the general population[@R8] and in patients with various medical conditions such as autoimmune diseases,[@R9] liver disease,[@R13] heart failure,[@R14] diabetes mellitus,[@R15] cancer,[@R17] posthaematopoietic stem cell transplantation,[@R18] postsurgery[@R19] and during pregnancy.[@R20] However, all these reviews summarised data mostly from populations outside Africa. As African populations differ from those of the rest of the world by their genetic background, specific living conditions in Africa including limited access to medical care, diagnosis and preventive interventions for VTDs, the burden of VTE might be different in African populations. Hence, this review seeks to provide a comprehensive overview of epidemiology of VTE and its prophylaxis in African populations.

Objective {#s2}
=========

The aim of this study is to conduct a systematic review and meta-analysis, with the aim to determine the prevalence, incidence, mortality and prophylactic measures of VTE in Africa.

Review questions {#s3}
================

Specifically, this review seek to answer the following questions:What is the prevalence and/or incidence of VTE among African populations?What is the mortality related to PE in Africa?What is the proportion of subjects at risk receiving VTE prophylaxis in African?

Methods and analysis {#s4}
====================

This protocol is written in accordance with recommendations from the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 statement.[@R22]

Criteria for considering studies for the review {#s4a}
-----------------------------------------------

### Inclusion criteria {#s4a1}

1.  All observational studies (cross-sectional, case series with at least 30 participants, case--control and cohort studies);

2.  Published between 1 January 1986 and 5 December 2016;

3.  Observational studies with sufficient data on: the prevalence and/or incidence of VTE, mortality rate of PE and use of VTE prophylaxis in African countries will be included without any language restrictions;

4.  Studies published in English or French.

### Exclusion criteria {#s4a2}

We will not consider:Studies conducted among populations of African origin residing outside Africa;Studies in which relevant data on VTE is lacking or impossible to extract;Letters, reviews, commentaries and editorials;Studies with inaccessible full text either online or from the corresponding author;For duplicates of studies published in more than report, the most comprehensive one reporting the largest sample size will be considered.

Search strategy for identifying relevant studies {#s4b}
------------------------------------------------

The search strategy will be devised in two steps

### Bibliographic database searches {#s4b1}

Relevant studies published on VTE in Africa will be searched via Medline, Embase, Scopus and African Journal online (AJOL) databases from 1 January 1986 to 5 December 2016, with no language restriction. Both text words and medical subject heading terms related to VTE will be used ([table 1](#T1){ref-type="table"}). The individual country names for the 54 African countries will be used as additional key search terms to increase the sensitivity of our search.[@R23]

###### 

Search strategy for PubMed

  Search   Search terms
  -------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#1      Venous thromboembolism (tw) OR Venous thromboembolic disease(tw) Or Deep vein thrombosis(tw) Or Pulmonary embolism(tw) OR Pulmonary Thromboembolism(MeSH terms) OR Thromboembolism (MeSH terms)
  \#2      (Africa\* OR Algeria OR Angola OR Benin OR Botswana OR 'Burkina Faso' OR Burundi OR Cameroon OR 'Canary Islands' OR 'Cape Verde' OR 'Central African Republic' OR Chad OR Comoros OR Congo OR 'Democratic Republic of Congo' OR Djibouti OR Egypt OR 'Equatorial Guinea' OR Eritrea OR Ethiopia OR Gabon OR Gambia OR Ghana OR Guinea OR 'Guinea Bissau' OR 'Ivory Coast' OR 'Cote d'Ivoire' OR Jamahiriya OR Kenya OR Lesotho OR Liberia OR Libya OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Mayotte OR Morocco OR Mozambique OR Namibia OR Niger OR Nigeria OR Principe OR Reunion OR Rwanda OR 'Sao Tome' OR Senegal OR Seychelles OR 'Sierra Leone' OR Somalia OR 'South Africa' OR 'South Sudan' OR 'St Helena' OR Sudan OR Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR 'Western Sahara' OR Zaire OR Zambia OR Zimbabwe OR 'Central Africa' OR 'Central African' OR 'West Africa' OR 'West African' OR 'Western) Africa' OR 'Western African' OR 'East Africa' OR 'East African' OR 'Eastern Africa' OR 'Eastern African' OR 'North Africa' OR 'North African' OR 'Northern Africa' OR 'Northern African' OR 'South African' OR 'Southern Africa' OR 'Southern African' OR 'sub Saharan Africa' OR 'sub Saharan African' OR 'subSaharan Africa' OR 'subSaharan African') NOT ('guinea pig' OR 'guinea pigs' OR 'aspergillus niger')
  \#3      \#1 and \#2

Second, the abstracts of all eligible articles will be reviewed and full-text articles will be accessed through PubMed, Embase, Scopus Database, AJOL, Google Scholar, Health InterNetwork Access to Research Initiative (HINARI), Sci Hub or journals' websites. The authors of papers whose full text cannot be obtained by the numerous internet-based sources will be directly contacted to provide them.

### Searching for others sources {#s4b2}

The references of all relevant articles and reviews will be scrutinised for additional data sources missed during our search, and their full texts will be retrieved as detailed above.

Selection of studies for inclusion in the review {#s4c}
------------------------------------------------

Two authors (CD and MNT) will independently assess eligible papers using an assessment guide to ensure that the selection criteria are reliably applied by all the team. These authors will carefully screen the titles and abstracts of papers obtained from the search, after which the full texts of potentially eligible papers will be retrieved by at least one author. Thereafter, they will independently review the full text of each potentially eligible study, compare their results and resolve any discrepancy by discussion and consensus. If a decision is not reached, a third review author (ATT) will be consulted for arbitration.

Assessment of methodological quality and reporting of data {#s4d}
----------------------------------------------------------

An adapted version of the Risk of Bias Tool for Prevalence Studies developed by Hoy *et al* [@R24] will be used to evaluate included studies for quality and bias, and will be applied to screened full-text articles. Assessment of the risk of selection and attrition bias will use the Cochrane guidelines available in Review Manager V.5.3 (<http://tech.cochrane.org/revman>). Furthermore, the reporting quality of each study will be assessed using the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines.

Data extraction and management {#s4e}
------------------------------

A data extraction sheet will be used to collect information on the last name of the first author, year of publication, region (Central, Eastern, Northern, Southern and Western Africa), country, study design, study area (rural versus urban), study setting (population-based vs hospital based), sample size, mean or median age, age range and male prevalence, disease specific to the study population (patients with cirrhosis, patients with tuberculosis, pregnant and postpartum women and postoperative patients), the total number of cases of VTE, number of new cases and/or number of deaths due to VTE in the study population. We shall report data on DVT and PE separately. Data on the number of patients at risk of VTE who did or did not receive prophylaxis for VTE will be extracted. For multinational studies, the prevalence, incidence or mortality will be reported for the individual countries. Where it is impossible to disaggregate data of multinational studies by country, the study will be presented as one and the countries in which the study was done will be highlighted.

Data synthesis and analysis {#s4f}
---------------------------

After data collection, a meta-analysis will be conducted for identical variables. Standard errors for the study-specific estimates will be determined from the point estimate and the appropriate denominators, assuming a binominal (or Poisson for incidence data) distribution. The study-specific estimates will be pooled using a random effects meta-analysis model to obtain an overall summary estimate of the prevalence and/or incidence across studies, after stabilising the variance of individual studies with the use of the Freeman-Tukey double arc-sine transformation.[@R25] Heterogeneity will be assessed using the X^2^ test on Cochrane's Q statistic[@R26] and quantified by calculating the I^2^.[@R27] Values of 25%, 50% and 75% for I^2^ represent, respectively, low, medium and high heterogeneity. We will assess the presence of publication bias using funnel plots and Egger's test.[@R28] Where substantial heterogeneity is detected, a subgroup analysis will be performed to investigate the possible sources of heterogeneity using the aforementioned variables and the study quality. In case of substantial heterogeneity, a narrative summary of our findings will be done. The inter-rater agreement for study inclusion will be assessed using Cohen's κ coefficient.[@R29] Data will be analysed using Stata software V.13 (Stata Corp).

Presentation and reporting of results {#s4g}
-------------------------------------

The study selection process will be summarised using a flow diagram. Quantitative data will be presented in evidence tables for individual studies as well as in summary tables and forest plots where appropriate. The quality scores and risk of bias for each eligible study will be reported accordingly. This will be tabulated and accompanied by narrative summaries. This may probably demonstrate a high incidence, prevalence and morbidity of VTE in Africa and a reduced use available methods of VTE prophylaxis.

Ethics and dissemination {#s4h}
------------------------

Ethics consideration is not required as the current study will be based on published data. This review is expected to provide relevant data to help in quantifying the magnitude of this disease in Africa. The final report of this study will be published in a peer-reviewed journal and the findings will be submitted to relevant health authorities.
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